Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations by Preto, Ana et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Proliferation and survival molecules implicated in the inhibition of 
BRAF pathway in thyroid cancer cells harbouring different genetic 
mutations
Ana Preto1,2, Joana Gonçalves1, Ana P Rebocho1, Joana Figueiredo1, 
Ana M Meireles1, Ana S Rocha1, Helena M Vasconcelos1,3, Hugo Seca1, 
Raquel Seruca1,4, Paula Soares*1,4 and Manuel Sobrinho-Simões1,4
Address: 1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-465, Porto, Portugal, 2Department of 
Biology, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal, 3Faculty of Pharmacy of the University of Porto, 4050-047 Porto, 
Portugal and 4Medical Faculty of the University of Porto, 4200-465 Porto, Portugal
Email: Ana Preto - apreto@ipatimup.pt; Joana Gonçalves - jgoncalves@cnc.cj.uc.pt; Ana P Rebocho - arebocho@ipatimup.pt; 
Joana Figueiredo - jfigueiredo@ipatimup.pt; Ana M Meireles - ameireles@ipatimup.pt; Ana S Rocha - arocha@ipatimup.pt; 
Helena M Vasconcelos - hvasconcelos@ipatimup.pt; Hugo Seca - hteixeira@ipatimup.pt; Raquel Seruca - rseruca@ipatimup.pt; 
Paula Soares* - psoares@ipatimup.pt; Manuel Sobrinho-Simões - ssimoes@ipatimup.pt
* Corresponding author    
Abstract
Background: Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are
inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using inhibitors on the
BRAF pathway as became an interesting therapeutic approach. In thyroid cancer cells the target molecules,
implicated on the cellular effects, mediated by inhibition of BRAF are not well established. In order to fill
this lack of knowledge we studied the proliferation and survival pathways and associated molecules
induced by BRAF inhibition in thyroid carcinoma cell lines harbouring distinct genetic backgrounds.
Methods: Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was
achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib. Proliferation
analysis was performed by BrdU incorporation and apoptosis was accessed by TUNEL assay. Levels of
protein expression were analysed by western-blot.
Results: Both BRAF RNAi and sorafenib inhibited proliferation in all the cell lines independently of the
genetic background, mostly in cells with BRAFV600E mutation. In BRAFV600E mutated cells inhibition of BRAF
pathway lead to a decrease in ERK1/2 phosphorylation and cyclin D1 levels and an increase in p27Kip1.
Specific inhibition of BRAF by RNAi in cells with BRAFV600E mutation had no effect on apoptosis. In the
case of sorafenib treatment, cells harbouring BRAFV600E mutation showed increase levels of apoptosis due
to a balance of the anti-apoptotic proteins Mcl-1 and Bcl-2.
Conclusion: Our results in thyroid cancer cells, namely those harbouring BRAFV600Emutation showed
that BRAF signalling pathway provides important proliferation signals. We have shown that in thyroid
cancer cells sorafenib induces apoptosis by affecting Mcl-1 and Bcl-2 in BRAFV600E mutated cells which was
independent of BRAF. These results suggest that sorafenib may prove useful in the treatment of thyroid
carcinomas, particularly those refractory to conventional treatment and harbouring BRAF mutations.
Published: 31 October 2009
BMC Cancer 2009, 9:387 doi:10.1186/1471-2407-9-387
Received: 18 November 2008
Accepted: 31 October 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/387
© 2009 Preto et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
Page 2 of 11
(page number not for citation purposes)
Background
A major event in the neoplastic transformation of thyroid
follicular cells is the constitutive activation of a single sig-
nalling pathway, the RET/PTC - RAS - BRAF - MEK - ERK
pathway. We, and others, have reported a high prevalence
of BRAF point mutations (BRAFV600E) in papillary thyroid
carcinomas (30% to 69%) and in anaplastic thyroid carci-
nomas (10% to 35%) [1,2]. In papillary thyroid carcino-
mas, BRAF mutations, RET/PTC rearrangements, and RAS
mutations are mostly mutually exclusive [3].
In melanomas, which also harbour BRAFV600E mutations,
it has been demonstrated that BRAFV600E activates the
MAPK pathway and controls proliferation of melanoma
cells through the regulation of cyclin D1 and of the cyclin-
dependent kinase inhibitor p27Kip1 [4-7]. Moreover, the
suppression of BRAFV600E in melanoma cells was demon-
strated to inhibit proliferation, transformation, invasion
and promote apoptosis [8-13].
In colon cancer suppression of BRAF in cell lines with
BRAFV600E  showed significant decreased proliferation
through cyclin D1 and p27Kip1 and induces apoptosis by a
significant decrease in the levels of anti-apoptotic protein
Bcl-2 [14].
In thyroid carcinoma-derived cell lines, it was observed
that inhibition of BRAF signalling by BRAF kinase inhibi-
tors or BRAF RNAi inhibits growth, transformation and
tumourigenicity of cell lines harbouring BRAFV600E muta-
tion, without any effect on apoptosis [15-19]. However,
the molecular targets underlying the cellular effects
induced by inhibition of the BRAF pathway in thyroid
cells remain to be determined.
Using thyroid carcinoma cell lines, with different genetic
profiles, we characterized the proliferation/survival asso-
ciated molecules using RNAi targeting BRAF and the
kinase inhibitor sorafenib, previously reported to inhibit
BRAF [20].
Methods
Cell lines culture conditions
Cell lines - 8505C, and C643 derived from anaplastic thy-
roid carcinomas and TPC1 derived from papillary thyroid
carcinoma - were grown in RPMI 1640 medium (with L-
glutamine and HEPES) supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin-streptomycin
(GIBCO, Invitrogen). All cells were grown in a humidified
incubator with 5% CO2 at 37°C.
BRAF RNA silencing
Small interference RNAs (siRNAs) sequences targeting
human BRAF were designed according to Hingorani et al
[8]: two of the oligos were specific for the V600E mutation
(BRAF-mutA and BRAF-mutB) and two oligos recognize
both the wild-type and mutated BRAF (BRAF-C1 and
BRAF-C2). The control (non-silencing) siRNA used was
that designed by Qiagen with the following target
sequence: 5'-AATTCTCCGAACGTGTCACGT-3'. All siR-
NAs were purchased from Qiagen. Cells were transfected
24 hours after platting in 6-well plates in RPMI supple-
mented with 10% foetal bovine serum (FBS). Transfection
was done using 3 μl of Lipofectamine 2000 (Invitrogen)
and 50 nM of siRNA. Control cells were transfected with
the siRNAs buffer alone. For the study of the uptake, cells
were cultured in 6-well plates, trypsinized and fixed with
4% paraformaldehyde. Cytospin preparations were
observed by fluorescence microscopy 24 hours after trans-
fection with FITC-labelled siRNA (Qiagen). For confirma-
tion of downregulation of BRAF protein, cells were seeded
and transfected as indicated above and processed at 24, 48
and 72 hours.
Drug treatment
Sorafenib stock solution was made at a concentration of
10 mM in DMSO and aliquots were kept at -20°C. Dose/
response curves and IC50 doses were obtained by count-
ing cell with trypan blue; briefly, cells were plated in 24
wells dishes and treated with increasing concentrations of
sorafenib (0,4 uM, 2 uM, 4 uM and 10 uM) or vehicle
(DMSO) in serum free conditions for different time
points (24 h and 48 h). After treatment, cells in suspen-
sion and adherent cells were counted with trypan blue.
After establishment of the dose range and optimal (IC50)
sorafenib concentration (4 μM, 48 h of treatment), cells
were plated in 6 well dishes at the appropriated cell den-
sity for proliferation (BrdU), apoptosis (TUNEL) and pro-
tein (Western blot) analysis.
Apoptosis assay
Cytospin preparations of both floating and attached cells
were collected and fixed with 4% paraformaldehyde (15
min) at room temperature. Cells were washed in PBS and
permeabilized with 0.1% Triton X-100 in 0.1% sodium
citrate (2 min) on ice. The TdT mediated dUTP Nick End
Labeling (TUNEL) analysis was performed using the "In
situ cell death detection kit, fluorescein" (Roche®), follow-
ing the manufacturer's instructions.
Assessment of DNA synthesis by BrdU incorporation
Cells were labelled by incubation in 10 μM bromodeoxy-
uridine (BrdU) for 1 h, fixed with 4% paraformaldehyde
and nuclear incorporation was detected by immunofluo-
rescence assay. The proportion of positive nuclei (BrdU
index) was determined from a count of >500 cells.
Western blot analysis
Cells were lysed for 5 min at 4°C using RIPA buffer (1%
NP-40 in 150 mM NaCl, 50 mM Tris (pH 7.5), 2 mMBMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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EDTA), containing phosphatase and protease inhibitors.
Proteins were quantified using a modified Bradford assay
(Biorad). Protein samples (25 mg) were separated in 8%,
10% or 12% SDS/PAGE gels depending on the molecule
to be analyzed and electroblotted to Hybond ECL mem-
brane (Amersham Biosciences). The primary antibodies
used were purchased from the following sources: anti-
phospho p44/42 MAPK (Thr202/Tyr204), anti-p44/42
MAPK total were from Cell Signalling. Anti-BRAF, anti-
Mcl-1, anti-p27, anti-CD1, anti-actin, anti-RAF-1 were
from Santa Cruz Biotechnology. Anti-Bcl-2 was from
Dako. Secondary antibodies (goat anti-rabbit and goat
anti-mouse) were conjugated with peroxidase (Santa Cruz
Biotechnology) and visualized by the ECL detection sys-
tem (Amersham). Quantization of the specific signal was
performed using Quantity One software from Bio-Rad.
Statistical analysis
Two-tailed paired Student's t-test was used to perform sta-
tistical analysis. In all analysis P < 0.05 was required for
statistical significance. Statistical analysis was done using
StatView software program (PC version).
Results
We tested the effect of BRAF inhibition by RNAi and sor-
afenib in cell lines representing the various genetic pro-
files found in thyroid tumours in vivo: 8505C harbours a
homozygous BRAFV600E mutation, TPC1 harbours a RET/
PTC1 rearrangement and wild-type for BRAF, and C643
harbours a RASG13R mutation and wild-type BRAF [21],
recently demonstrated to be unique thyroid cancer cell
lines origin [22].
Effect of BRAF inhibition by RNAi in proliferation and 
apoptosis of thyroid cancer cells
We used RNAi technology to specifically inhibit the BRAF
gene. A panel of four BRAF siRNA oligonucleotides
(mutA, mutB, C1 and C2) [8] were tested in all cell lines.
After optimization (data not shown) the siRNA oligonu-
cleotide BRAF-C2 which target both wild-type and
mutated BRAF was selected, being the most potent at
reducing BRAF levels after 48 hours of exposure. Transfec-
tion with BRAF-C2 siRNA led to inhibition of BRAF levels
in all cell lines (Figure 1). No effect on the RAF-1 protein
levels was observed using the BRAF-C2 siRNA (Figure 1).
BRAF silencing induces a significant inhibition in the pro-
liferation of all the cell lines (p < 0.05) in comparison to
the siRNA control: 8505C (64.0%), TPC1 (37.9%), and
C643 cell line (18.9%). In the case of the C643 cell line
the decrease in proliferation was less pronounced but also
reached the statistical significance. The effect was more
evident in the cell line harbouring BRAF mutation
(8505C) (Figure 2a).
Western-blot analysis of BRAF expression levels after RNAi treatment Figure 1
Western-blot analysis of BRAF expression levels after RNAi treatment. BRAF protein expression is inhibited in cells 
treated with siRNA BRAF-C2 in comparison to the blank, transfection control and siRNA control. Inhibition of BRAF was effi-
cient in all cell lines. No alteration was seen in the levels of RAF-1 protein. The figure presented is representative of at least 
three independent experiments.BMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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The knockdown of BRAF induced a slight increase in
apoptosis in 8505C cells (Figure 2b) as measured by
TUNEL assay. In the TPC1 cell line, inhibition of BRAF led
to a significant increase in apoptosis (Figure 2b). No sig-
nificant effect on apoptosis was observed in the C643 cell
line (Figure 2b).
In all cell lines analyzed the controls (blank, transfection
control and siRNA control) were not significantly differ-
ent between them for proliferation and apoptosis analysis
(Figure 2).
Effect of sorafenib in proliferation and apoptosis of 
thyroid cancer cells
Sorafenib a kinase inhibitor, developed as a RAF-1 kinase
inhibitor [23,24] was shown to inhibit both the wild-type
and the V600E mutant BRAF in vitro [20]. Sorafenib has
been approved by the Food and Drug Administration
(FDA) for therapy of renal cell carcinoma and is under
clinical trials for melanoma and thyroid cancer [25]. A
fixed dose of 4 μM of sorafenib for 48 h was selected since
it represents the approximate IC50, for all cell lines (see
Material and Methods).
Treatment with sorafenib induced a significant inhibition
of proliferation (measured by BrdU incorporation) in all
cell lines analyzed (p < 0.05) (Figure 3a and 3c-f). In com-
parison with the vehicle control, the percentage of cells
incorporating BrdU diminished 96.9% in 8505C, 97.1%
in TPC1 and 83.7% in C643 cell lines (Figure 3a).
To determine if the effect of sorafenib on cell growth was
only due to inhibition of proliferation or in alternative
was mediated by increased apoptosis, we performed a
TUNEL assay. We observed an increase in the number of
apoptotic cells in all the cell lines tested. In 8505C cell line
there was a significant increase in apoptosis of 17 fold in
comparison to the control (p < 0.05) (Figure 3b and 3c, d,
g-j) whereas the level of apoptosis seen in TPC1 and C643
cell lines did not reach the level of statistical significance
(Figure 3b). Sorafenib induces inhibition of proliferation
in all cell lines and induces a significant increase in apop-
tosis in the cell line harbouring BRAFV600E mutation (Fig-
ure 3). The results obtained in apoptosis with BRAF
silencing suggest that the apoptotic effect mediated by sor-
afenib does not depend solely on the inhibition of BRAF.
Effect of BRAF inhibition in ERK phosphorylation of 
thyroid cancer cells
BRAF specific inhibition by RNAi reduced ERK phosphor-
ylation levels in 8505C and C643 cell lines, in compari-
son to the control siRNA (Figure 4b). In the TPC1 cell line
(with a RET/PTC1 rearrangement) no differences were
seen in the levels of phosphorylated ERKs (Figure 4b).
Protein analysis revealed that sorafenib reduced ERK
phosphorylation levels in all the cell lines after 1 h of
treatment comparing with DMSO control (Figure 4a).
ERK phosphorylation was variable and transient at the
other time points analyzed (12 h, 24 h, 48 h) and in the
different cell lines, as previously described by Ouyang et al
[19] (Figure 4a).
Analysis of target molecules implicated in the cellular 
effects induced by inhibition of BRAF pathway
We studied the expression of proteins involved in cellular
proliferation (cyclin D1 and p27Kip1) and apoptosis path-
BrdU and TUNEL analysis after RNAi treatment Figure 2
BrdU and TUNEL analysis after RNAi treatment. (a) BRAF knockdown using BRAF-C2 siRNA induces a significant (*p 
< 0.05) decrease in BrdU incorporation in comparison to the siRNA control in the three cell lines. (b) Inhibition of BRAF had 
no major effect on apoptosis as measured by TUNEL assay in 8505C and C643. In TPC1 cells there was a significant (*p < 0.05) 
increase in apoptosis when compared with the controls. All values presented are the mean of at least three independent 
experiments. In both, BrdU and TUNEL analysis, siRNA control did not produce any significant effect in comparison to the 
blank and transfection controls.BMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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Figure 3 (see legend on next page)BMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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ways (pNFkB, pBad, Mcl-1, Bcl-2, Bax and XIAP) that are
likely to be implicated in the cellular effects induced by
inhibition of BRAF pathway either by RNAi or by soraf-
enib treatment.
Cell cycle related proteins analysis
BRAF silencing by RNAi leads to inhibition of cyclin D1
expression in all the cell lines analyzed mostly in BRAF
mutated cell line (8505C - Figure 5a). We also observed a
pronounced increase in the levels of p27Kip1 in 8505C and
TPC1 and no apparent alterations in C643 (Figure 5a).
These results suggest that the inhibition of proliferation
observed after BRAF silencing is regulated through cyclin
D1 and p27Kip1 levels.
After treatment with sorafenib we observed inhibition of
cyclin D1 expression in the three cell lines, exhibiting dif-
ferent inhibition kinetics at different time points analyzed
(Figure 5b). With regard to p27Kip1we observed an
increase of p27Kip1 in 8505C and TPC1, whereas in C643
cells an increase was observed after 1 h and 48 h respec-
BrdU and TUNEL analysis after sorafenib treatment Figure 3 (see previous page)
BrdU and TUNEL analysis after sorafenib treatment. Sorafenib inhibited the proliferation of thyroid carcinoma derived 
cell lines and induced apoptosis in the cell line harbouring the BRAFV600E mutation (8505C). (a) Proliferation analysis by BrdU 
assay after treatment with sorafenib at a dose of 4 uM for 48 hours: all treated cell lines showed a significant (*p < 0.05) 
decrease in the percentage of cells incorporating BrdU in comparison to the vehicle (DMSO); (e, f) Representative photos of 
8505C cell line showing decreased incorporation of BrdU in treated cells when compared with the DMSO control. (b) Apop-
tosis analysis by TUNEL assay after treatment with sorafenib at a dose of 4 uM for 48 hours. The cell line harbouring BRAFV600E 
mutation (8505C) showed a significant increase (*p < 0.05) in the levels of apoptotic cells after sorafenib treatment in compar-
ison to cell lines harbouring wild-type BRAF (TPC1, C643). (g, h, i, j) Representative photos of 8505C cell line showing 
increased TUNEL labelling in treated cells when compared with the DMSO control. DAPI: counter stain to detect nuclei in 
FITC-stained cells in TUNEL and BrdU assays (c, d- phase contrast 20×; e, f, g, h, i, j, 40×). All values presented are the 
mean of at least three independent experiments.
Western-blot analysis of ERK phosphorylation levels after sorafenib and RNAi treatment Figure 4
Western-blot analysis of ERK phosphorylation levels after sorafenib and RNAi treatment. (a) Sorafenib treatment 
leads to decreased levels of ERK phosphorylation. Cells were treated in serum free conditions with 4 uM of sorafenib or 
DMSO and proteins were extracted after 1 h, 12 h, 24 h and 48 h. The levels of phosphorylated ERKs after treatment were 
quantified relative to total ERKs and compared with the DMSO control. As shown in the graph, the levels of ERK phosphoryla-
tion decreased in all the cell lines at different time points, the levels were variable and transient in the time points analyzed in 
the different cell lines. (b) BRAF knockdown by RNAi induced decreased levels of ERK phosphorylation 48 h after transfection 
as detected by Western-blot analysis. Quantification of the levels of phosphorylated ERKs relative to total ERKs and compared 
with RNAi control (see graph), showed that BRAF-C2 siRNA inhibited ERK phosphorylation in 8505C and C643, but not in 
TPC1 cells. All values presented are the mean of at least three independent experiments.BMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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tively, and an apparent decrease was observed in the other
time points (Figure 5c).
Apoptosis related proteins analysis
Inhibition of BRAF by RNAi had no effect on the expres-
sion of Mcl-1 and Bcl-2 in the three cell lines (data not
shown); this finding fits with the absence of significant
differences detected in the apoptotic levels after transient
inhibition of BRAF in the cell lines 8505C and C643.
Although a significant increase in the level of apoptosis
was seen in TPC1 cells (Figure 3b), none of the studied
apoptotis related proteins showed alterations. Interest-
ingly, the different cell lines treated with sorafenib
showed different levels of Mcl-1 and Bcl-2 (two anti-apop-
totic proteins). In 8505C cells, the decrease in Mcl-1 levels
was transient, increasing after 48 h of treatment (Figure
6a). In C643 cells, we observed a decrease in Mcl-1 levels
after 12 h and 24 h and an increase after 1 h and 48 h of
treatment (Figure 6a). The decrease was more pronounced
in the cell line with BRAFV600E. We also analyzed the
expression of the anti-apoptotic protein Bcl-2 and
observed that there was a pronounced decreased of Bcl-2
levels in 8505C cells after sorafenib treatment. In the
remaining cell lines there was either no change, or only
slight variations in the levels of Bcl-2 (Figure 6b). The bal-
ance in the levels of the anti-apoptotic proteins Mcl-1 and
Bcl-2 overtime might be, in part, responsible for the differ-
ent effects of sorafenib on apoptosis in 8505C cells, in
contrast to TPC1 and C643 cells. The results obtained on
Mcl-1 and Bcl-2 levels roughly parallel those obtained in
Western-blot analyses of p27 and cyclin D1 expression levels after sorafenib and RNAi treatment Figure 5
Western-blot analyses of p27 and cyclin D1 expression levels after sorafenib and RNAi treatment. (a) Inhibition 
of BRAF by BRAF-C2 siRNA decreased the levels of cyclin D1 in all the cell lines and increased the levels of p27Kip1 in 8505C 
and TPC1 cells, but not in C643 cells as demonstrated in the Western-blot analysis and by quantification of the levels of cyclin 
D1 and p27 relative to actin (data not shown). (b, c) Sorafenib treatment induced alterations in cyclin D1 and p27Kip1 at differ-
ent time points depending on the cell line. The graphs represent the quantification of the levels of cyclin D1 and p27Kip1 pro-
teins relative to actin and compared with the DMSO control. (b) Treatment with 4 μM of sorafenib led to decreased 
expression of cyclin D1 at different time points and at different levels in all the cell lines. (c) Concerning the levels of p27Kip1 
after treatment with sorafenib: in 8505C cells there was an increase in all the time points except after 12 h; in TPC1 there is an 
increase after 12 h, 24 h and 48 h; in C643 there is an increase after 48 h. All values and figures presented are the mean of at 
least three independent experiments.BMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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the study of the levels of apoptosis in the same cell lines
(compare Figure 3 and 6). The cell line that show a higher
induction of apoptosis (8505C) by sorafenib is the one in
which the decrease in the levels of Mcl-1 and Bcl-2 after
treatment were more pronounced (Figure 6). No altera-
tions were observed in the expression levels of other mol-
ecules implicated in survival pathways (pNFkB, pBad, Bax
and XIAP) by RNAi or sorafenib treatment (data not
shown)
Discussion
BRAF a serine/threonine kinase, known to activate the
MAPK pathway has been found mutated in several
tumours, namely melanoma, colorectal carcinoma and
Western-blot analyses of Mcl-1 and Bcl-2 expression levels after sorafenib treatment Figure 6
Western-blot analyses of Mcl-1 and Bcl-2 expression levels after sorafenib treatment. (a) Sorafenib treatment led 
to a marked decrease in the levels of Mcl-1 in the cell line with mutated BRAFV600E (8505C) at all the time points analyzed 
except after 48 h in 8505C. Mcl-1 levels in TPC1 and C643 cells varied at the different time points after treatment, as shown in 
the graph (c): in TPC1 cells there was a decrease at all time points; in C643 cells there was a variable response with a increase 
seen at 1 h and 48 h. (b) Sorafenib induced alterations in the levels of Bcl-2 in the three cell lines. Levels of Bcl-2 protein were 
quantified, as shown in the graph (c): in 8505C cells the levels of Bcl-2 decreased at all time points; in TPC1 cells there was a 
marked increase after 1 h and 48 h; in C643 cells the levels of Bcl-2 remain unchanged at all time points except at 24 h where 
there was a increase. All values presented are the mean of at least three independent experiments.BMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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thyroid carcinoma [3,4,26]. In thyroid carcinomas the
molecules and pathways associated to the effect of BRAF
inhibition in cellular proliferation and survival are not
fully understood. We aimed to characterize in thyroid can-
cer cell lines with different genetic background those mol-
ecules implicated in proliferation/survival using RNAi
targeting BRAF and the kinase inhibitor sorafenib.
Our results show that both approaches induce inhibition
of proliferation in all the cell lines, regardless of the
genetic background, although RNAi leads to a more pro-
nounced effect in proliferation in BRAFV600E mutated cell
line. Our results support the hypothesis that thyroid can-
cer cells with activated BRAF are more dependent on the
BRAF-ERK pathway for proliferation than those with RAS
or RET/PTC1 activation.
BRAF is implicated in proliferation control through MAPK
pathway downstream targets [27]. BRAF inhibition by
RNAi strongly reduces ERK activation in the cell line har-
bouring the BRAFV600E mutation, is also effective in the
cell line with RASG13R, but has no effect in ERK activation
in the cell line with RET/PTC rearrangement. The higher
levels of ERK inhibition achieved in the BRAF mutated cell
line, by RNAi, demonstrates that in these cells BRAF is the
main activator of ERKs. Our results in C643 cell line are in
accordance with the activation of ERK proteins by acti-
vated RAS through BRAF dependent mechanism [28]. The
absence of effect in ERK phosphorylation after BRAF inhi-
bition by RNAi in TPC1 cell line suggests that RET/PTC1
activates ERK by a mechanism independent of wild-type
BRAF. Our results suggest that RET/PTC1-mediated cell
proliferation requires BRAF kinase but not BRAF-MAP
kinase pathway. Mitsutake et al [29] have shown that, in a
background of RET/PTC3 activation, BRAF is required for
MAPK activation in PCCL3 cells. Our results, in TPC1 cell
line, suggest that in a background of RET/PTC1 other mol-
ecules may signal to the MAPK pathway. In TPC1 cells we
have previously suggested that RAF-1 could be the pre-
ponderant RAF isoform [30], and this might explain that
specific inhibition of BRAF in this cell line does not have
an effect on ERK activation at variance with RAS and BRAF
mutated cells.
We showed that sorafenib inhibits efficiently ERK activa-
tion in all the cell lines regardless of the underlying onco-
genic alteration. However, the inhibition of ERK
phosphorylation secondary to the treatment with soraf-
enib was variable and transient in the different cell lines,
as previously demonstrated by Ouyang et al using other
RAF kinase inhibitors [19]. This variation between cell
lines can be associated to its effect against angiogenesis-
related receptor tyrosine kinases such as VEGFR -2 and -3,
along with other kinases such as PDGFR-β, Flt-3 and c-Kit
[20,23,24,31,32]. The level of ERK inhibition achieved in
TPC1 by sorafenib, and not by BRAF RNAi, indicates that
sorafenib targets other molecule(s) besides BRAF, namely
RET/PTC oncogenic protein itself, as previously advanced
[23,31].
The results we obtained with BRAF siRNA in cells with
mutated BRAF (8505C) show that BRAFV600E-ERK signal-
ling is important in the regulation of proliferation. Several
proteins have been shown to be targeted by the BRAF/
MEK/ERK signalling pathway in distinct tumours models
(melanoma, colorectal and thyroid carcinomas); those
proteins include cyclin D1 and p27Kip1, implicated in cell
cycle regulation [6,7,14,33]. In normal thyrocytes cyclin
D3 is the predominant D-type cyclin, but in papillary car-
cinoma cells with BRAF mutation cyclin D3-CDK4 activa-
tion is lost [30]. In thyroid cancer cell lines with RET/PTC
or BRAF oncogenic mutations cyclinD1-CDK4 complex is
more abundant than cyclinD3-CDK4, suggesting the
dominant character of cyclin D1 complexes formation in
thyroid oncogenesis [30]. This is in accordance with our
results showing that, in thyroid cancer cell lines a decrease
in proliferation parallel with a decrease in cyclin D1 lev-
els. Our results showed, furthermore, that in cells with
RET/PTC1 rearrangement, inhibition of BRAF by RNAi
besides decreasing cyclin D1 levels, increases the levels of
p27Kip1 and leads to the inhibition of proliferation, which
was independent of ERK inhibition. In a background of
RAS activation (C643 cell line), BRAF inhibition decreases
the levels of phosphorylated ERKs and cyclin D1 and has
no effect on the levels of p27Kip1. This results support that
p27Kip1 might be regulated directly by activated RAS, as
previously advanced by Jones et al [34].
The variability observed in the expression levels of cyclin
D1 and p27Kip1 in all cell lines after treatment with soraf-
enib, may also result from the ability of sorafenib to func-
tioning as a multikinase inhibitor [20,23,24,31,32].
We have shown that selective downregulation of BRAF
does not induce apoptosis in thyroid cells with BRAF
mutation at variance with sorafenib that induces marked
apoptosis in BRAFV600E mutated cells. In melanoma cell
lines it was shown that sorafenib treatment can induce cell
death, leading to Bad dephosphorylation, decrease in the
levels of Bcl-2 and Bax activation [11,35]. In addition, sor-
afenib has also been shown to downregulate the prosur-
vival Bcl-2 family member Mcl-1 which may be a
mechanism through which the compound mediates its
pro-apoptotic effect [36]. Our results suggest that in thy-
roid cells with BRAFV600E oncogenic activation the effect of
sorafenib in apoptosis depends upon the balance in the
levels of the anti-apoptotic proteins Mcl-1 and Bcl-2 and
not in the levels of Bad and Bax (data not shown), as pre-
viously demonstrated in melanoma cells [11,35,36]. We
have also shown that NFkβ and XIAP do not seem to beBMC Cancer 2009, 9:387 http://www.biomedcentral.com/1471-2407/9/387
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involved in that process. The most striking downregula-
tion of the levels of Mcl-1 and Bcl-2 proteins was observed
in the cell line harbouring mutated BRAF (8505C) in
which sorafenib induced also the highest levels of apopto-
sis. These results fit with previous reports in melanoma
cell lines [35,36]. These effects were not observed after
BRAF specific inhibition by RNAi, suggesting a BRAF-
independent mechanism for sorafenib in the regulation of
Mcl-1 and Bcl-2 expression and induction of apoptosis, in
cells with mutated BRAF. Inhibition of BRAF by siRNA
induces apoptosis only in TPC1 cells harbouring RET/
PTC1 indicating that wild-type BRAF seems to be impor-
tant in survival of these cells.
The mechanism by which sorafenib downregulated the
levels of Mcl-1 is likely to depend on enhanced proteo-
some-mediated Mcl-1 degradation [36]. This downregula-
tion of Mcl-1 by sorafenib is not cell type dependent or
selective for BRAF-mutated cell lines since this effect was
observed in all cells lines analysed some of them without
BRAF mutation [35,36]. The mechanism by which soraf-
enib downregulates the levels of Bcl-2 is not well under-
stood. This mechanism seems to be cell dependent as it
was only observed in melanoma cell lines by Yu C et al
[36] and in thyroid carcinoma cells by us in the present
study. Bcl-2 downregulation in melanoma cells after sor-
afenib treatment occurs in cell lines harbouring BRAF
mutation but seems to be ERK-independent [36]. How-
ever, in our study we observed a more pronounced
decreased of Bcl-2 levels in BRAF mutated thyroid cells
which was dependent on ERK activation.
Conclusion
In this study we described for the first time, to the best of
our knowledge, the effect of both sorafenib and specific
siRNA for BRAF in thyroid cancer cells and associated
molecules. Our results show that BRAF plays a major role
in the proliferation of thyroid carcinoma cells independ-
ently of the oncogenic activation, suggesting a role of
wild-type BRAF also in RET/PTC and activated RAS signal-
ling pathways. Our results also show that p27Kip1 and cyc-
lin D1 proteins are important in the regulation of
proliferation via BRAFV600E-ERK signalling and BRAF does
not seem to be a major protein for the survival of thyroid
cancer cells.
Treatment of thyroid carcinomas is usually achieved
through the use of radioactive iodine (131I). Although the
majority of thyroid carcinomas respond well to radioiod-
ine therapy, there are thyroid tumours resistant to this
therapy, that are inoperable and have lost radioactive
avidity [25]. Taking into account the high prevalence of
BRAF mutations in thyroid tumours it is tempting to con-
sider the use of BRAF inhibitors as a therapeutic approach
in these cancers. A recent phase II clinical trial of sorafenib
showed a significant anti-tumour activity in advanced thy-
roid cancer without molecular characterization [37]. Our
results indicate that sorafenib might be particularly potent
in thyroid tumours harbouring BRAF mutations since, in
addition to inhibition of proliferation it is also able of
inducing apoptosis in these settings.
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